EmilyYing H NChewMD

Ophthalmology • Bethesda, MD

Retinal Disease

Physician

Join to view full profile

Dr. Chew is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chew's full profile

Already have an account?

Office
National Institutes Of Healt Dr
Bethesda, MD 20892
Phone+1 301-496-6583

Summary

I am a board certified ophthalmologist specialized in medical retina. I am currently the the Director of the Division of Epidemiology and Clinical Applications (DECA), at the National Eye Institute, the National Institutes of Health in Bethesda, Maryland. I am also the Chief of the Clinical Trials . I obtained my medical degree and residency training in ophthalmology at the University of Toronto, School of Medicine, in Toronto, Canada. I completed my fellowship in Medical Retina at the Wilmer Eye Institute, the Johns Hopkins Medical Institutes and the U. of Nijmegen, the Netherlands.

My research interest includes designing and conducting phase I/II clinical trials and epidemiologic studies in chronic retinovascular diseases such as age-related macular degeneration, diabetic retinopathy, the leading causes of blindness in the US. I am actively involved with leadership roles in the conduct of clinical trials such as Age-Related Eye Disease Study, the Age-Related Eye Disease Study 2, the Actions to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, the Macular Telangiectasia Project (Mac Tel Project) with phase 1 to 3 clinical trial using ciliary neurotrophic factor (CNTF). I chair the current international study, known as the AMD Ryan Initiative Study (ARIS), which evaluates the natural course of early AMD. Finally, I collaborate with colleagues at the National Library of Medicine (NLM/NIH) utilizing of artificial intelligence/deep learning on the detection and progression of age-related macular degeneration.

Education & Training

University of Toronto Faculty of MedicineClass of 1977

Certifications & Licensure

MD State Medical License 1987 - 2026
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Age-Related Eye Disease Study 2 (AREDS2) Start of enrollment: 2006 Sep 01
Completed
Phase 3
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Start of enrollment: 2003 Oct 01
Completed
Phase 3
Age-Related Eye Disease Study (AREDS) Follow-Up Start of enrollment: 2008 Jun 02
Active, not recruiting
AMD Phenotype and Genotype Study Start of enrollment: 2012 Nov 05
Completed
AMD Ryan Initiative Study (ARIS) Start of enrollment: 2018 Feb 12
Completed
PROMINENT-Eye Ancillary Study (Protocol AD) Start of enrollment: 2018 Jan 15
Terminated
Phase 3
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On Start of enrollment: 2018 May 23
Completed
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration Start of enrollment: 2018 May 23
Completed
Study of Dark Adaptation in Age-Related Macular Degeneration Start of enrollment: 2011 May 16
Active, not recruiting
Roles: Principal Investigator, Contact
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene Start of enrollment: 2010 Aug 23
Recruiting
Roles: Contact, Principal Investigator
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation Start of enrollment: 2018 May 14
Active, not recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Dark Adaptation in Participants With Age-Related Macular Degeneration Start of enrollment: 2017 Jun 16
Recruiting
Roles: Contact, Principal Investigator
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation Start of enrollment: 2018 Apr 20
Active, not recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

244 citations
The Age-related Eye Disease Study 2 (AREDS2): Study Design and Baseline Characteristics (AREDS2 Report Number 1)
Emily Y. Chew, Traci E Clemons, John Paul SanGiovanni, Ronald P. Danis, Amitha Domalpally
Ophthalmology. 2012-11-01
2 citations
Associations between Age-related Eye Diseases and Charles Bonnet Syndrome in Participants of the Age-Related Eye Disease Study 2. AREDS2 Report Number 26.
Jimmy T Le, David Peprah, Elvira Agrón, Tiarnan D L Keenan, Traci E Clemons
Ophthalmology. 2021-08-20
49 citations
Rationale, Design, and Methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)
Emily Y. Chew, Walter T. Ambrosius, Letitia T Howard, Craig M. Greven, Samantha Johnson
The American Journal of Cardiology. 2007-06-18

Journal Articles

Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration
Srinivas R Sadda, Brandon Busbee, Emily Y Chew, Neil M Bressler, JAMA
Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity
Emily Y Chew, Catherine Cukras, Paul A Sieving, Investigative Ophthalmology and Visual Science

Press Mentions

AI-Based Systems Can Help Identify Rapidly Advancing Age-Related Macular DegenerationMarch 14th, 2023
Cohort Finds Lutein and Zeaxanthin Reduce Effects of AMDJune 13th, 2022
Week in Review: Inhaled Steroids Raise IOP, Antioxidants Appear Safe in AMD Patients, Brolucizumab Approved for DMEJune 4th, 2022
Join now to see all

Grant Support

Mactel2National Eye Institute2010–2011
Mactel1National Eye Institute2010–2011
Medical Retina FellowshipNational Eye Institute2009–2011
FIND (Familial Investigation Of Nephropathy In Diabetes)National Eye Institute2009–2011
Age-Related Eye Disease Follow-Up Study (AREDS) Follow-Up StudyNational Eye Institute2009–2011
Accord (Action To Control Cardiovascular Risk In Diabetes)National Eye Institute2009–2011
Serum Factors In Diabetic EyesNational Eye Institute2009–2010
Ranibizumab (Rhufab V2) For Advanced Ocular Disease Of VNational Eye Institute2005
Evaluation/Diagnosis- Potential Subject-RetinovascularNational Eye Institute2005
Evaluation-Treatment Protocol-Patients- Retinal DiseaseNational Eye Institute2005
Accord(Action-Control Cardiovascular Risk In Diabetes)National Eye Institute2005
The Raman StudyNational Eye Institute2003–2005
Serum Factors In Diabetic EyesNational Eye Institute2003–2005
FIND (Familial Investigation Of Nephropathy In Diabetes)National Eye Institute2003–2005
DPP (Diabetes Prevention Program)National Eye Institute2003–2005
Diabetic Macular Edema StudyNational Eye Institute2002–2005
Age-Related Eye Disease Study (AREDS)National Eye Institute2002–2005
Screening For Evaluation/Diagnosis Of Potential SubjectsNational Eye Institute2004
Ranibizumab For Advanced Ocular Disease Of VHL DiseaseNational Eye Institute2004
Evaluation &Treatment Protocol For PatientsNational Eye Institute2004
Accord Action To Control Cardiovascular Risk In DiabetesNational Eye Institute2004
Screening For The Evaluation/Diagnosis Of Potential SubjNational Eye Institute2003
Range Study Of Lutein Supplementation In Persons Over AGNational Eye Institute2003
Evaluation And Treatment Protocol For Patients With RetiNational Eye Institute2003
Antioxidant For DmeNational Eye Institute2003
Accord (Action To Control Cardiovascular Risk In DiabeteNational Eye Institute2003
Screening For Retinovascular DiseasesNational Eye Institute2002
Range Study Of Lutein Supplementation Over Age 60National Eye Institute2002
Evaluation And Treatment Protocol Of Retinal DiseaseNational Eye Institute2002